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The aim of cancer therapy is to eradicate cancer without affecting healthy tissues.
Current options available for treating colorectal cancer (CRC), including surgery,
chemotherapy or radiotherapy, usually elicit multiple adverse effects and frequently fail
to completely remove the tumor cells. Thus, there is a constant need for seeking cancer
cell-specific therapeutics to improve the course of cancer therapy and reduce the risk of
relapse. In this review we elaborate on the mechanisms underlying the immunotherapy
with dendritic cells (DCs) and cytokine-induced killer (CIK) cells, and summarize their
effectiveness and tolerability available clinical studies. Finally, we discuss the up-to-date
combinatorial adoptive anti-cancer immunotherapy with CIK cells co-cultured with DCs
that recently showed encouraging efficacy and usefulness in treating malignant disease,
including CRC.
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INTRODUCTION
Colorectal cancer is the second in woman and the third in men most commonly diagnosed cancer
worldwide (Siegel et al., 2015), accounted for approximately 1.2 million new cases and over 600.000
deaths annually (Torre et al., 2015). Surgical resection is the first choice procedure for patients
suffering from CRC, and is frequently followed by radio- or chemotherapy. For early staged CRC
patients, the combined course of treatment results in 5-year survival rate of up to 80% (Zhu
et al., 2014). Nevertheless, surgical resection with adjuvant radio- or chemotherapy is often poorly
tolerated by patients due to many severe side effects directly related to complications after surgery,
including infections and bleedings, and indirectly to psychological trauma, nausea, vomiting, and
fever. Therefore, new, more patient friendly and especially effective treatment is necessary to avoid
tumor recurrence, and enhance the response rate to therapy.
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; APCs, antigen presenting cells; CIK, cytokine-
induced killer cells; CRC, colorectal cancer; CTT, cytotoxic T lymphocytes; DCs, dendritic cells; DTH, Delayed Type
Hypersensitivity; ER, endoplasmic reticulum; i-DCs, induced DCs; IDO, indoleamine 2,3-dioxygenase; IFN-γ, interferon
gamma; IFNs-I, interferons type I; IL-1, interleukin-1; IL-2, interleukin-2; IL-6, interleukin-6; IL-12, interleukin-12; LAKs,
lymphokine-activated killers; mDCs, myeloid dendritic cells; MHC, major histocompatibility complex; MST, medium
survival time; NOD, nucleotide oligomerization domain; OS, overall survival; PBMS, peripheral blood mononuclear cells;
pDCs, plasmacytoid dendritic cells; PFS, progression-free survival; TAAs, tumor associated antigens; TAP, transporters for
antigen presentation; Th cell, T helper cell.
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Colorectal cancer is a heterogenous disease in terms of its
molecular characteristics, clinical manifestations, and sensitivity
to treatments. Along with accumulation of genetic alterations
(e.g., genomic and chromosomal instabilities) and epigenetic
changes that constitute the main forces for tumor development,
immune pattern of the tumor microenvironment seems to be
the major predictor of patient’s survival in a variety of primary
tumors (Maby et al., 2015). High density of T cells and CD8+
T cells cytotoxic orientation or mature DCs are considered
as a target in the treatment of large group of cancers such
as colorectal, lung, breast, pancreatic and melanoma cancers
(Al-Shibli et al., 2008; Pagès et al., 2009; Mahmoud et al., 2011;
Remark et al., 2013). Adaptive and innate immune system can
protect the host from tumor development through mechanisms
of immunosurveillance (Mlecnik et al., 2010; Stoll et al.,
2015). Cancer immunotherapy involves the use of therapeutic
modalities, which stimulate the host’s anti-tumor response by
altering the effector cell number and secretion of soluble
mediators, and decreases the host’s suppressor mechanisms
by modulating immune checkpoints. The immunotherapy
represents the most promising new cancer treatment approach,
also among CRC patients. Patients suffering from CRC are in
an immunosuppressed state when they undergo radiotherapy,
surgery, or chemotherapy and often exhibit compromised
immune responses; therefore, it is recommended to target
dysfunctional cells to achieve most promising therapeutic
results and simultaneously recover anti-cancer immunity to
support immune response to tumor cells. DCs, responsible
for the activation of T-cells, and CIK cells, which induce the
secretion of a diverse array of cytokines, are rapidly evolving
immunotherapeutic targets in eradicating residual cancer cells
(Yang et al., 2011). The therapy has already been used in the
treatment of chronic myeloid leukemia and other types of cancer
such as liver, kidney, breast, and prostate (Wang et al., 2009).
Understanding of the molecular interactions between immune
system and tumor cells has significantly improved in the
last decade, leading to the development of DC-CIK adoptive
immunotherapy, which encompasses the introduction of DCs
in combination with the CIK cells. The immunotherapy with
DC-CIK reduces the severity of adverse effects, namely grade
III and IV leukopenia, thrombocytopenia and anemia, which
commonly occurs as a consequence of conventional cancer
therapy, improves overall quality of life and prolongs the survival
of CRC patients (Lin et al., 2016).
MECHANISM OF ACTION OF DCS
Dendritic cells are well-characterized APCs (Steinman, 1991),
which reside in peripheral tissues. The role of DCs is to
capture, process and present phagocytosed antigens, including
TAAs, express lymphocyte costimulatory molecules and secrete
cytokines, such as IL-12, IL-15 and type I interferons (IFNs I)
to initiate primary immune response in resting naive T cells
(Pulendran et al., 2008; Legitimo et al., 2014).
Dendritic cells comprise multiple subsets with different
morphologic, phenotypic, and functional properties. There are
two main classes of DCs, similar for both mice and humans:
mDCs, also called classical DCs, and pDCs, which originate
from CD34+ bone marrow precursors (Figure 1). Under certain
conditions, both types can be also propagated from monocytes
(Shortman and Naik, 2007; Pulendran et al., 2008). The two DC
subsets possess distinct features: mDCs express CD11c marker
and are considered as principal producers of IFNs I, whereas
pDCs express mainly CD123 and IDO, an enzyme participating
in the generation of regulatory T cells (Koido et al., 2013).
A detailed discussion of DC subtypes can be found elsewhere
(Dudek et al., 2013; Ma et al., 2013; Legitimo et al., 2014). In
healthy conditions, DCs occur in an immature or semi-mature
state and are usually localized in various non-lymphoid organs
and tissues. Immature DCs are responsible for the uptake
and process of peptides. They are able to respond to various
inflammatory signals, e.g., toll-like receptors (TLR), NOD-like
receptors, scavenger receptors, and inflammatory mediators,
chemokines and cytokines (Niu et al., 2014). Upon activation,
immature DCs migrate to lymphoid tissues and interact with T
cells. Active DCs produce and secrete IL-12, which induces cell
differentiation of lymphocytes T CD4 + into antigen-specific
effector Th cells e.g., Th1, Th2, Th17, and increases production
of interferon-gamma (IFN-γ) and cytotoxic activity of CTL,
essential for antitumor immune activity (Koido et al., 2013). The
distinction between mature and immature DCs relates to their
phenotypic and functional properties. Maturation of DCs occurs
when the cell can upregulate MHC class II molecules and several
surface ligands, including CD80, CD83 and CD86 (Märten et al.,
2001). Moreover, fully matured DCs can control the balance
between inflammatory, e.g., IL-6, immunostimulatory, e.g., IL-12
cytokines and immunosuppressive cytokines (Xie et al., 2006).
However, existing evidence suggests that DCs may occur in
states, since they exhibit high functional plasticity, i.e., DCs are
able to express immunostimulating and/or immunesuppresive
factors depending on microenvironmental conditions that
affect their differentiation, maturation, polarization and
activation; however, even in multiple environmental milieus
morphologically different DC subsets are able to stimulate T cell
proliferation and modulate their response (Manicassamy and
Pulendran, 2011).
Various endogenous and exogenous stimuli affect maturation
of DCs by changing the processing and presentation of the
antigen, e.g., activated natural killer (NK) cells acquire the
ability to defeat DCs that have failed to undergo complete
maturation. Moreover, DC–NK interaction induces generation
of various cytokines by both cell types, and besides enhancing
DC maturation, also promotes the proliferation of NK cells.
Endogenous antigens are degraded into peptides by proteasomes
in the cytosol and together with TAP are transferred to ER, where
they create complexes with MHC class I molecules. The peptide-
MHC I complexes is subsequently presented to CD8+ T cells.
This form of antigen presentation is available not only for DCs
but also for other nucleated cells (Ma et al., 2013). Exogenous
antigens in turn are processed in endosomes, loaded onto MHC
class II molecules, and activate CD4+ T cells and cause their
further polarization to Th cells. This process is restricted only to
APCs (Ma et al., 2013).
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FIGURE 1 | Comparison of surface markers, toll-like receptor (TLR), chemokine receptors (CCR) and C-type lectin receptors (CLRs) profiles between
two major populations of naturally circulating DCs- human blood myeloid and plasmacytoid DCs- in the peripheral blood of humans (Mckenna et al.,
2005; Bamboat et al., 2009; Reizis et al., 2011).
Metastasis and tumor stage are related to higher infiltrations
of DCs in the tumor tissue (Gordon et al., 2014). DCs
modulate innate and adoptive immunity, affect oncogenesis,
especially tumor progression, and therefore influence response
to cancer therapy (Bloy et al., 2014). However, the presence
of tumor cells may also drive DCs into state of tolerance and
immunosuppression, resulting in their decreased or completely
inhibited activity of initiating the immune response. Functional
impairments of DCs have been reported in various types of
cancer, such as chronic myeloid leukemia, liver cancer as well as
CRC (Miller et al., 2004).
Dendritic cell-based interventions aim at (re)activating
the endogenous cancer-specific immune response, which
de facto constitutes an anti-cancer vaccine. Exploiting naturally
circulating DCs can be performed either by isolating pDCs
or mDCs and stimulating them ex vivo (with adjuvants
and antigens), in vivo (by means of nanoparticles coated
with antibodies against DCs-specific cell surface receptors),
and DC-derived exosomes (Bol et al., 2013; Bloy et al.,
2014).
GENERAL MECHANISM OF CIK CELLS
Cytokine-induced killer cells are ex vivo expanded heterogeneous
population of lymphocytes T CD8+ with additional NK cells
phenotype. They are generated by an in vitro extraction
of PBMC and its further exposition to IFN-γ, anti CD-3
antibody, and prolong propagation in presence of high-dose
IL-1 and IL-2 (Wang et al., 2011; Schlimper et al., 2012).
After maturation, when the majority of cells exhibit granular
lymphocyte morphology and express NK and T-cell markers, CIK
cells are transferred to the recipient in autologous or allogeneic
settings (Zhao et al., 2015).
The lytic activity of CIK cells is driven mainly by CD3+CD56+
cells that can coexpress both the T-cell marker CD3 and
the NK cell marker CD56 (Pievani et al., 2011). They
were first described in 1991 by Schmidt-Wolf et al. (1991),
who concluded CIK cells to have higher proliferation and
strengthened cytotoxic properties against tumor cells compared
to their progenitors LAKs. CIK cells display non-MHC-
restricted NK-like anti-tumor activity against allogenic and
syngeneic hematological malignancies (Sangiolo et al., 2008).
They secrete proinflammatory cytokines, predominantly IFN-γ
and IL-4. Due to their CLT phenotype, CIK cells are also
capable of eliminating cells presenting MHC molecules (Wang
et al., 2009). Mechanisms used by CIK cells to terminate
cancer cell include release of granules, such as granzymes
and perforin. Along with NK cells, macrophages, monocytes,
and neutrophils, CIK cells can mediate cytotoxicity through
ADCC (Kohrt et al., 2012). It is therefore possible that besides
recognizing cancer cells without prior antigen sensitization in
a non-MHC restricted manner, CIK cells anti-tumor activity
might be enhanced by adding specific monoclonal antibodies
targeting ADCC (Wang et al., 2014). Since CIK cells can be
produced by a simple approach and exert anti-tumor activity
in vitro, they seem to be suitable tools for the treatment of
solid and hematopoietic tumors (Li et al., 2012). Autologous
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and allogenic CIK cells have been already evaluated in the
treatment of different tumor types (NCT0076910, NCT01186809,
NCT02886897, NCT00394381, NCT00815321, NCT01871480,
and NCT01232062).
DC–CIK INTERACTION
Based on available data the adoptive immunotherapy with
DC-CIK encompass either the infusion of DCs (the amount
of infused cells ranges from 1 to 5 × 107) following the
administration of CIK cells (the amount of cells range from 2
to 15 × 109) or autologous tumor lysate pulsed DC-CIK cells
infused intravenously (NCT02202928) (Zhu et al., 2014).
According to different clinical trials, DCs can be injected
subcutaneously, intravenously or intradermally, in turn CIK
cells are usually administered intravenously or intradermally
(NCT01956630, NCT02491697, and NCT02202928).
Any dysfunction of either DC or CIK cells may cause
inefficient immune response, which consequently enables cancer
cells to spread. Interactions between molecules on the surface of
mature DCs and CIK cells cause an increased activation of each of
these populations; however, the exact mechanism of action is still
not fully understood. The stage of DCs maturation determines
DC–CIK interaction and its function (Lin et al., 2016). Mature
DCs provide necessary signals for proliferation of CIK cells by
increasing their cytotoxic and cytolytic capabilities; immature
DCs are unable to trigger this reaction and are consequently
killed by CIK cells (Qu et al., 2014). DC–CIK interaction also
causes a significant increase in the number of costimulatory and
antigen-presenting molecules on DCs surface, which provides
the cell with greater tumor-fighting capabilities (Figure 2).
Combination of DC-CIK in cancer therapy, compared to each
therapy alone, results in an enhanced immune response in treated
patients (n = 100) and greater therapeutic effects (Zhu et al.,
2014). Numerous studies provide evidence that DC-CIK were
effective in the treatment of multiple solid tumors, e.g., breast
cancer, non-small-cell lung cancer, without causing any serious
adverse reactions.
The fact that distinct subsets of DCs precursors can be
activated and mobilized by various cytokines, e.g., in humans
pDCs can be regulated in vivo with Flt4 ligand or G-CSF, whereas
other blood DC subsets only by Flt3L, it additionally provides
an individual approach for manipulating of immune responses
in humans (Arpinati et al., 2000; Pulendran et al., 2000). This
approach may constitute another way of improving the effect of
therapy with DC-CIK.
However, it has to be mentioned that multiple parameters can
modulate the quality of immune responses through DC targeting
(Ueno et al., 2011). Thus, some major issues need consideration
during DC vaccine development:
-biological function of the DC subsets that is anticipated to
deliver antigens,
-the type of activation signaling and immune response that the
DC can induce,
-the selection of antigens and their formulation that will
induce the antigen-specific response
-the receptors expressed by the particular subset of DCs.
FIGURE 2 | Simplified scheme showing interactions between DCs and CIK cells. mDCs are also able to crosstalk with NK cells, prototypical effector
cells of innate immunity. Both mDC and NK cells reciprocally stimulate and regulate their functions. For example upon activation, NK cells acquire the ability to
defeat immature DCs. On the other hand, activated IFN-α-generating DCs can also stimulate NK cells and initiate antigen-specific T- and B-cell responses. The
crosstalk appears via cell-to-cell interaction and largely involves the activation of NK cells via transmembrane TNF-α. Activated NK cells can also directly kill target
tumor cells through several mechanisms involving TRAIL, ADCC, IFN-γ, NO or by the release of granzymes, perforins, granules. ADCC, antibody-dependent cellular
cytotoxicity; CTL, C-type lectins; IFN-γ, interferon γ; MHC II, major histocompatibility complex II; NK cell, natural killer cell; NO, nitric oxide; TCR, toll-like receptors;
TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
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BENEFICIAL EFFECTS OF DC-CIK
THERAPY
One of great advantages of immunotherapy is an easy evaluation
and monitoring of patients’ response to therapy based on DTH
reaction. According to Zhu et al. (2014; Lin et al., 2016), among
100 patients with CRC, more than 60% developed positive cell-
mediated cytotoxicity response to the treatment with DC-CIK,
assessed in DTH skin test. Adverse events occurred in less than
30% of recruited patients and included fever, insomnia, sore
joints and skin rush (Niu et al., 2014; Zhang et al., 2016).
However, validity and efficacy of DTH can be affected by the
tumor environment and therefore the obtained results should be
treated with caution.
Dendritic cell-cytokine-induced killer cell-based
immunotherapy combined with chemotherapy prolongs
PFS in patients with CRC, and increases OS rate to almost
4 months, when compared to chemotherapy alone (Lin
et al., 2016). Similar outcomes were reported in the study by
Niu et al. (2014) in which 44 out of 70 patients with CRC
developed positive immune response after DC-CIK-based
immunotherapy, which prolonged their MST. No severe adverse
events were observed; however, similarly to the study by
Zhu et al. (2014) patients experienced mild inconveniences,
e.g., insomnia, fever, anorexia, skin rush or joint soreness.
The respective increase in PFS and OS were almost 9 and
15 months, respectively, for patients treated with DC-CIK
therapy additionally to chemotherapy. The incorporation of
the adjuvant immunotherapy for patients undergoing primary
chemotherapy resulted in general improvement in quality of life,
including physical strength, appetite, better sleep and increase in
body weight (Zhan et al., 2012). Finally, DC-CIK therapy proved
to decrease the recurrence and metastasis rate in CRC patients
(Lin et al., 2016).
Dendritic cell-cytokine-induced killer therapy targets tumor
cells without attacking other cells of the organism, which it
is not associated with toxicity, and thus make it a viable
treatment option for patients in poor health (Hui et al.,
2009). As opposed to chemotherapy, DC-CIK therapy induces
fewer and less severe adverse effects, and also limits the
side effects caused by chemotherapy itself. Adjuvant DC-CIK
therapy to primary chemotherapy lowers the frequency of severe
treatment induced complications – hematological toxicities
such as leukopenia, anemia and thrombocytopenia as well as
nausea, vomiting and abdominal liver function (Lin et al.,
2016).
Worth mentioning, tumors that develop radiation or
chemotherapy resistance, still remain a suitable target for
immunotherapy (Dasgupta et al., 2011). A combined approach
to use conventional anti-cancer therapy to kill the bulk of cancer
cells and immunotherapy (e.g., DCs as adjuvants) to improve
immunization against tumor cells, can be even more effective in
treating cancer.
Currently, there are few clinical trials, both ongoing and
still recruiting, assessing the effect of the autologous tumor
lysate pulsed DC-CIK treatment in CRC patients (NCT02202928,
NCT01839539, and NCT02415699).
LIMITATIONS OF ANTI-CRC THERAPY
Chemotherapy has many imperfections: not only its sensitivity
declines over time, but often causes numerous adverse effects,
for example nausea and vomiting. This line of treatment is also
associated with severe toxicity, which deteriorates general health
of patients and leads to discontinuation of treatment (Dasgupta
et al., 2011).
In contrast to chemotherapy, the side effects of
immunotherapy include insomnia, fever, anorexia, diarrhea,
joint soreness and general fatigue (Wood et al., 2000). They are
minor, occur rarely and are mostly self-resolving; usually no
special treatments and hospitalizations are necessary. In some
cases, the anti-inflammatory drugs are used to resolve side effects
such as fever. The treatment with DC-CIK does not prompt
autoimmune reactions (Niu et al., 2014). In some singular cases
limited toxicity may appear; however, lowering the dose of
the treatment resolves the side effects and allows the patients
to continue the treatment (Zhan et al., 2012). Nonetheless,
because the positive cell-mediated cytotoxicity response to DC
vaccine and CIK cell therapy is developed in around 60% of CRC
patients, the therapy is not effective for all (Niu et al., 2014).
Currently, peripheral blood is the main source of DC-CIK. As
the therapy should be personalized for each patient, the repeated
collection of blood can be difficult and may imply a considerable
costs, which narrow the number of recipients. In some cases, e.g.,
elderly patients or patients in poor health, obtaining the number
of cytotoxic cells necessary for the therapy may pose a significant
challenge and limit the utility of the therapy.
There is still insufficient number of clinical trials that evaluate
the effectiveness of DC-CIK therapy in patients with CRC, and
which determine the probability of the occurrence of adverse
effects. Randomized controlled trials with larger sample sizes
or meta-analysis are warranted to provide evidence for further
application of this therapy.
CONCLUSION
Immunotherapy has fewer side effects than standard treatment
with chemo- or radiotherapy and is generally more potent in
preventing their onset. Recent studies present new treatment
options for patients suffering from CRC, focusing predominantly
on DC-CIK therapy, which stimulate the immune system
of a patient against cancer. Being in the spotlight of cancer
prevention, the therapy with DC-CIK shows a great potential
in alleviating symptoms of CRC, improving the quality of
life of patients and simultaneously prolonging their lifespan.
Several studies recommend to include the DC-CIK therapy as
adjuvant for currently applied anti-cancer therapy; however,
the conclusions were drawn based on a small number clinical
trials having possibly high heterogeneity and publication bias.
Moreover, due to variability of studies (e.g., tumor stage, cell
phenotype, cell purity) and parameters assessed throughout,
the outcomes could not be unified. Despite promising
outcomes obtained so far, there is no strong evidence that
the DC-CIK therapy shows a clear advantage over currently used
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treatment options. Undoubtedly, combined immunotherapy and
chemotherapy may have a synergistic effect on OS compared with
chemotherapy alone. However, the definite efficacy of DC-CIK
therapy is still not explicit and warrants evaluation.
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